[go: up one dir, main page]

EP4058020A4 - Composition de mésylate de gémifloxacine pharmaceutique orale solide à profil de libération et mécanisme de désintégration améliorés - Google Patents

Composition de mésylate de gémifloxacine pharmaceutique orale solide à profil de libération et mécanisme de désintégration améliorés Download PDF

Info

Publication number
EP4058020A4
EP4058020A4 EP19957856.8A EP19957856A EP4058020A4 EP 4058020 A4 EP4058020 A4 EP 4058020A4 EP 19957856 A EP19957856 A EP 19957856A EP 4058020 A4 EP4058020 A4 EP 4058020A4
Authority
EP
European Patent Office
Prior art keywords
solid oral
oral pharmaceutical
release pattern
improved release
disease mechanism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19957856.8A
Other languages
German (de)
English (en)
Other versions
EP4058020A1 (fr
Inventor
Ersin Yildirim
Bayram Kanik
Fatma ÖZTÜRK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santa Farma Ilac Sanayi AS
Original Assignee
Santa Farma Ilac Sanayi AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santa Farma Ilac Sanayi AS filed Critical Santa Farma Ilac Sanayi AS
Publication of EP4058020A1 publication Critical patent/EP4058020A1/fr
Publication of EP4058020A4 publication Critical patent/EP4058020A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP19957856.8A 2019-12-26 2019-12-26 Composition de mésylate de gémifloxacine pharmaceutique orale solide à profil de libération et mécanisme de désintégration améliorés Pending EP4058020A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2019/051235 WO2021133279A1 (fr) 2019-12-26 2019-12-26 Composition de mésylate de gémifloxacine pharmaceutique orale solide à profil de libération et mécanisme de désintégration améliorés

Publications (2)

Publication Number Publication Date
EP4058020A1 EP4058020A1 (fr) 2022-09-21
EP4058020A4 true EP4058020A4 (fr) 2023-04-12

Family

ID=76574933

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19957856.8A Pending EP4058020A4 (fr) 2019-12-26 2019-12-26 Composition de mésylate de gémifloxacine pharmaceutique orale solide à profil de libération et mécanisme de désintégration améliorés

Country Status (2)

Country Link
EP (1) EP4058020A4 (fr)
WO (1) WO2021133279A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2491920A1 (fr) * 2011-02-25 2012-08-29 Deva Holding Anonim Sirketi Comprime effervescent, sachet et sirop en poudre de gemifloxacine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE051133T2 (hu) * 2010-11-01 2021-03-01 Melinta Subsidiary Corp Gyógyászati készítmények
EP2491921A1 (fr) * 2011-02-25 2012-08-29 Deva Holding Anonim Sirketi Conservation de la forme anhydre de gemifloxacine
CN102949369B (zh) * 2012-10-30 2014-06-25 丽珠医药集团股份有限公司 甲磺酸吉米沙星药物组合物的制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2491920A1 (fr) * 2011-02-25 2012-08-29 Deva Holding Anonim Sirketi Comprime effervescent, sachet et sirop en poudre de gemifloxacine

Also Published As

Publication number Publication date
WO2021133279A1 (fr) 2021-07-01
EP4058020A1 (fr) 2022-09-21

Similar Documents

Publication Publication Date Title
EP4417606A4 (fr) Nouveau composé de pyrimidopyridine, composition pharmaceutique de celui-ci et utilisation associée
EP4045480A4 (fr) Formulations pharmaceutiques
EP3778608C0 (fr) Dérivés de carbamoylpyridone polycycliques, compositions pharmaceutiques et utilisation de ceux-ci
EP4149470A4 (fr) Formulations pharmaceutiques et leurs utilisations
EP3556369A4 (fr) Composition pharmaceutique orale à libération prolongée et contrôlée d'olaparib et ses utilisations
BRPI0821732A2 (pt) Formulações de liberação controlada , forma de dosagem sólida, e, uso da formulação de liberação controlada
EP4072520C0 (fr) Compositions pharmaceutiques contenant du cabotégravir
EP4074334A4 (fr) Composition pharmaceutique et son utilisation
CL2007003289A1 (es) Compuestos derivados de biciclocarboxiamida; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades provocadas por la hiperactivacion del receptor vc1 como dolor, enfermedad de vejiga, inflam
BRPI0814666A2 (pt) composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida
BR112012003280A2 (pt) composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
EP4005591A4 (fr) Composition pharmaceutique combinée antinéoplasique et son application
EP3449944A4 (fr) Nanoparticules à usage oral pour l'administration de gène et composition pharmaceutique les contenant
BR112017028140A2 (pt) formulações farmacêuticas
CL2007002875A1 (es) Composicion farmaceutica recubierta por una pelicula que comprende capecitabina y al menos un disgregante, util en el tratamiento del cancer para pacientes que tienen dificultad para tragar las formas de dosificacion solidas orales.
EP3481381A4 (fr) Forme de dosage orale avec composition de médicament, couche barrière et couche de médicament
EP4221690A4 (fr) Compositions pharmaceutiques
EP3785698A4 (fr) Composition pharmaceutique d'edaravone
EP3784214C0 (fr) Forme galénique pharmaceutique orale liquide
EP4135699A4 (fr) Compositions pharmaceutiques
EP4365182A4 (fr) Dérivé anticancéreux de gemcitabine et utilisation pharmaceutique contre le cancer
BRPI0821454A2 (pt) Formulação farmacêutica, excipiente para a preparação de formulação farmacêuticas de liberação lenta, e, processos para a produção de um excipiente de liberação lenta, e de uma forma farmacêutica.
EP3790543A4 (fr) Compositions et formes posologiques pour administration orale
EP3868371A4 (fr) Nouvelle composition pharmaceutique
EP4110301A4 (fr) Composition pharmaceutique pour administration par voie orale

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220615

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20230313

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/04 20060101ALI20230306BHEP

Ipc: A61K 9/28 20060101ALI20230306BHEP

Ipc: A61K 31/4375 20060101AFI20230306BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250109